Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-20T22:33:25.575Z Has data issue: false hasContentIssue false

Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients with Schizophrenia: The 1 Year ENLIGHTEN-2-Extension

Published online by Cambridge University Press:  10 May 2021

Rene Kahn
Affiliation:
Icahn School of Medicine at Mount Sinai, New York, NY, USA
Bernard Silverman
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Lauren DiPetrillo
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Christine Graham
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Ying Jiang
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Jiani Yin
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Adam Simmons
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Vasudev Bhupathi
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Bei Yu
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Craig Hopkinson
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Davidd McDonnell
Affiliation:
Alkermes Pharma Ireland Limited, Dublin, Ireland
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

Combination olanzapine and samidorphan (OLZ/SAM) is in development for treatment of schizophrenia and bipolar I disorder and is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. This 52-week open-label extension study (NCT02873208; ENLIGHTEN-2-EXT) in schizophrenia assessed the safety and tolerability of OLZ/SAM. Methods: Patients completing the 24-week, randomized, double-blind, phase 3 ENLIGHTEN−2 study comparing weight gain with OLZ/SAM vs olanzapine were eligible for ENLIGHTEN-2-EXT enrollment. Initial OLZ/SAM doses were based on olanzapine dose (10 or 20 mg) received at the conclusion of ENLIGHTEN-2; subsequent olanzapine dose adjustments were allowed. The samidorphan dose (10 mg) remained fixed throughout. Assessments included adverse events (AEs), weight, waist circumference, metabolic laboratory parameters, and Positive and Negative Syndrome Scale (PANSS) scores. Analyses were based on observed results using descriptive statistics. Baseline was relative to the first OLZ/SAM dose in the extension study.

Results

265 patients received OLZ/SAM; 167 (63.0%) completed the extension study. Common AEs (= 5%) were weight decreased (n=23; 8.7%), extra dose administered (n=21; 7.9%), headache (n=18; 6.8%), and weight increased (n=16; 6.0%). At week 52, mean (SD) change from baseline for weight and waist circumference was −0.03 (6.216) kg and −0.35 (6.115) cm, respectively. Changes in fasting lipid and glycemic parameters were generally small and remained stable over 52 weeks. PANSS total scores remained stable during the extension.

Conclusions

OLZ/SAM was generally well tolerated over 52 weeks. Weight, waist circumference, metabolic laboratory parameters, and schizophrenia symptoms remained stable throughout the study.

Funding

Alkermes, Inc.

Type
Abstracts
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Footnotes

Presenting Author: Adam Simmons